EssilorLuxottica and MidEuropa have entered into an agreement for EssilorLuxottica to acquire Optegra, the integrated ophthalmology platform operating in the UK, Czech Republic, Poland, Slovakia and the Netherlands.
“With the acquisition of Optegra, we are stepping into a new frontier – one where comprehensive eyecare, advanced diagnostics, therapeutic interventions and surgical treatments come together in one seamless platform,” commented Francesco Milleri, chairman and chief executive officer (CEO), and Paul du Saillant, deputy CEO at EssilorLuxottica.
“We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with healthcare potential, and diagnostic capabilities that will be able to detect conditions ranging from neurodegenerative diseases to cardiovascular dysfunction.
“Optegra and its experienced doctors will bring new medical capabilities to our group, enabling us to address patients’ needs with the most advanced vision care technologies and treatments in one trusted system that will anchor our med-tech aspirations. Powered by our growing AI and big data capabilities, we will be able to broaden our impact and deliver the most personalised and seamless patient journey.”
The Optegra group, under the Optegra, Lexum and Iris brands, operates an extensive network of over 70 eye hospitals and diagnostic facilities across Europe, offering medically necessary ophthalmic treatments and elective vision correction procedures supported by AI in pre- and post-op stages.
“We believe EssilorLuxottica is the ideal partner to lead Optegra into its next phase of growth and innovation, and we wish them every success as they build on the strong foundation we have helped create,” commented Robert Knorr, managing partner at MidEuropa.
“Joining forces with EssilorLuxottica marks a transformative chapter for Optegra,” commented Dr Peter Byloos, CEO of Optegra Eye Health Care. “This partnership not only accelerates our growth potential but also enhances our ability to deliver advanced, digital and integrated eyecare solutions to all our patients.”
The transaction is expected to close later in 2025 pending regulatory approvals and other customary closing conditions.
Read the EssilorLuxottica statement in full.
Image from stock.